Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

The lawsuit involves the "off-label" uses of the anti-psychotic drug Zyprexa, the Jackson (Miss.) Clarion Ledger reported.

The suit alleges representatives of Eli Lilly persuaded Mississippi doctors to prescribe the drug to patients suffering from conditions such as anxiety, mood swings and disturbed sleep when the drug is only approved to treat bipolar disorder and schizophrenia.

Tim Balducci, Mississippi special assistant attorney general, told the Clarion Ledger Eli Lilly targeted Mississippi because the state's Medicaid system cannot determine when a medication is prescribed for non-approved uses.

The Indianapolis-based Eli Lilly has 30 days to respond to the suit.

Copyright 2006 by United Press International

Explore further: People use handshakes to sniff each other out

add to favorites email to friend print save as pdf

Related Stories

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Recommended for you

Study shows who benefits most from statins

3 hours ago

New research suggests that widely used statin therapy provides the most benefit to patients with the highest genetic risk of heart attack. Using a relatively straightforward genetic analysis, the researchers ...

How much overdetection is acceptable in cancer screening?

3 hours ago

People have highly variable views on how much overdetection is acceptable in cancer screening, finds a UK survey in The BMJ this week. The authors say invitations for screening "should include clear information on the li ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.